Table 3.
Univariate analysis for MDA achievement at 6 or 12 months of treatment
| Parameters | MDA achievement at 6 or 12 months | p Value* | |
| Yes | No | ||
| Province, n (%) | |||
| Western | 2 (14.3) | 12 (85.7) | 0.019 |
| Ontario | 42 (56.0) | 33 (44.0) | |
| Quebec | 27 (52.9) | 24 (47.1) | |
| Maritimes | 8 (36.4) | 14 (63.6) | |
| Gender, n (%) | |||
| Male | 45 (59.2) | 31 (40.8) | 0.031 |
| Female | 28 (40.6) | 41 (59.4) | |
| Age, mean (SD) | 46.6 (12.0) | 51.6 (10.7) | 0.011 |
| MDGA (VAS cm)†, mean (SD) | 4.3 (2.4) | 5.9 (2.0) | <0.001 |
| PtGA (VAS mm)†, mean (SD) | 39.7 (24.7) | 56.8 (24.9) | <0.001 |
| Pain (VAS mm)†, mean (SD) | 35.6 (24.4) | 55.1 (23.2) | <0.001 |
| HAQ†, mean (SD) | 0.7 (0.6) | 1.3 (0.6) | <0.001 |
| SJC28†, mean (SD) | 3.4 (3.8) | 5.4 (4.4) | 0.001 |
| TJC28†, mean (SD) | 3.8 (4.1) | 8.8 (6.8) | <0.001 |
| Enthesitis count†,‡, mean (SD) | 0.7 (1.4) | 2.0 (3.3) | 0.013 |
| Baseline biological agent | |||
| GLM | 48 (53.9) | 41 (46.1) | 0.158 |
| IFX | 31 (42.5) | 42 (57.5) | |
*p Value was assessed with χ2 for categorical variables or with non-parametric Mann-Whitney U test for continuous variables.
†Denotes disease parameters at baseline.
‡Among all patients (with and without enthesitis).
GLM, golimumab; HAQ, Health Assessment Questionnaire; IFX, infliximab; MDA, minimal disease activity; MDGA, physician’s global assessment of disease activity; PtGA, patient’s global assessment; SJC28, 28-item swollen joint count; TJC28, 28-item tender joint count; VAS, Visual Analogue Scale.